Development of an Ion-Pair HPLC Method for Determination of Acebutolol in Pharmaceuticals

A simple and accurate ion-pair reversed-phase high-performance liquid chromatographic (RP-HPLC) method has been developed and validated for determination of acebutolol (ACE) in tablet dosage forms. Both ACE and ambroxol (internal standard) were well separated using a reversed phase column and a mobile phase consisting of a mixture of methanol-0.05 M acetic acid (containing 8 mM sodium 1-heptanesulfanate) (65:35 v/v) with pH adjusted to 3.2 with triethylamine. The mobile phase was pumped at 0.80 mL min^?1 flow rate and ACE was detected by diode-array detection at 240 nm. The retention times for ACE and internal standard (IS) were 4.574 and 8.236 min, respectively. A linear response (r = 0.9998) was observed in the range of 0.27–2.93 μg mL^?1 in mobile phase. The limit of detection and limit of quantification were found as 0.07 and 0.23 μg mL^?1 in the mobile phase. Validation parameters such as precision, accuracy, selectivity, reproducibility, and system suitability tests were also determined. The excipients did not interfere with the assay of ACE in tablet dosage forms. It is suggested that the proposed method can be used for routine quality control and dosage-form assay of ACE.     

Development of Stability Indicating HPLC–UV Method for Determination of Daclatasvir and Characterization of Forced Degradation Products

A simple and sensitive stability indicating high performance liquid chromatography method was developed for quantification of Daclatasvir hydrochloride in bulk and tablet dosage forms. The analysis was performed on water symmetry analytical column (150 mm?×?3.9 mm, 5 µm), packing octyl silica (Si-[CH₂]₇-CH₃) C8. Mobile phase containing potassium phosphate buffer (pH 2.0) and acetonitrile (38: 62) v/v was used at flow rate 0.7 mL min^?1 for isocratic elution. Detection was performed on 304 nm using UV detector. The method was validated appropriately according to the requirements of United State Pharmacopeia and International Conference on Harmonization guideline Q2 (R1). Recovery, precision, linearity and specificity of the method were assured. The correlation coefficient for linearity ranged from 2 to 24 µg mL^?1 was (r?>?0.9999). The limits of detection and quantification of Daclatasvir were 0.08 and 0.28 µg mL^?1, respectively. Stability studies of Daclatasvir were performed under various stressed conditions, i.e., hydrolytic (acidic, basic and neutral), oxidation, photolytic and thermal conditions, according to International Conference on Harmonization Q1A (R2) and QIB Guidelines. The degradation products were resolved using proposed method and further characterized by MS, NMR and IR spectroscopic analyses. The proposed method was successfully applied to assay determination of bulk drugs and tablet dosage forms.     

Validated LC Determination of the Piroxicam-β-Cyclodextrin Inclusion Complex in Tablets and in Human Plasma

A simple, rapid, specific, sensitive HPLC method has been developed for the determination of piroxicam in the tablet dosage form and in human plasma. The method totally eliminates solvent extraction and time-consuming separation procedures. Plasma proteins were precipitated by addition of 3:1 (v/v) acetonitrile-methanol, ZnSO₄, and MgSO₄ and the supernatant was injected directly on to a 250 mm × 4.6 mm, 5 μm particle Spherisorb analytical column. Acetonitrile-methanol-0.04 mol L^?1 KH₂PO_4, 40:10:50 (v/v); pH 3.8, was used as mobile phase. The drug was detected by UV detection at 330 nm. The response was linear over the range of 0.01–10 μg mL^?1 and 0.025–5 μg mL^?1 in mobile phase and human plasma samples, respectively. The proposed method was used without interference from the endogenous substances, for determination of piroxicam in plasma samples obtained from healthy volunteers. The results revealed that the method would be useful in monitoring plasma levels of the drug during pharmacokinetic studies. Assay of piroxicam in its dosage forms for quality-control purposes could also be performed successfully by use of this method.     

Liquid Chromatography-Mass Spectrometry Hyphenation for Exhaustive and Unambiguous Characterization of Polyoxyethylene Surfactants

A rapid, specific and reliable high performance liquid chromatographic (HPLC) assay of sildenafil in pharmaceutical dosage forms has been developed and evaluated. Reversed phase chromatography was conducted using a mobile phase of methanol: water: acetonitrile (60:20:20) v/v/v, pH 6.1, 0.1% glacial acetic acid, and detection at λ 290 nm. The recovery and coefficient of variation from six tablets containing 50 mg of sildenafil were 100.90% and 0.45% respectively. Replicate regression analysis of three standard plots in the concentration range (0.01–0.2) μg mL^?1 obtained on three different days gave a correlation coefficient >0.999 and the coefficient of variation of the slopes <1.5%. The assay was precise within day and between days as indicated by ANOVA test. It is suggested that the proposed HPLC method should be used for routine quality control and dosage form assay of sildenafil citrate. The proposed method was also used to study the stability of sildenafil citrate in different dosage forms of the drug.     

Simple and Sensitive High-Performance Liquid Chromatographic Method for Determination of Transdermally Applied Flurbiprofen in Rat Plasma and Excised Skin Samples

A simple reversed-phase HPLC method has been developed for determination of flurbiprofen in rat plasma, excised skin extract, and transdermal patch formulations. The mobile phase was methanol–1% (v/v) phosphoric acid in water, 80:20 (v/v), at a flow rate of 0.5 mL min^-1; ibuprofen was used as internal standard. Flurbiprofen and ibuprofen was detected by UV absorption at 254 nm and 220 nm, respectively. The limit of quantitation was 0.1 µg mL^-1. The response was linearly dependent on concentration in the range 0.1–10 µg mL^-1, and accuracy and reproducibility were good. At these concentrations intraday and interday assay variability were below 8%. Recovery of flurbiprofen was greater than 94% over the linear range of calibration plot.     

Quality-by-design-based development and validation of a stability-indicating UPLC method for quantification of teriflunomide in the presence of degradation products and its application to in-vitro dissolution

A systematic design-of-experiments was performed by applying quality-by-design concepts to determine design space for rapid quantification of teriflunomide by the ultraperformance liquid chromatography (UPLC) method in the presence of degradation products. Response surface and central composite quadratic were used for statistical evaluation of experimental data using a Design-Expert software. The response variables such as resolution, retention time, and peak tailing were analyzed statistically for the screening of suitable chromatographic conditions. During this process, various plots such as perturbation, contour, 3D, and design space were studied. The method was developed through UPLC BEH C18 2.1?×?100?mm, 1.7-µ column, mobile phase comprised of buffer (5?mM K₂HPO₄ containing 0.1% triethylamine, pH 6.8), and acetonitrile (40:60 v/v), the flow rate of 0.5?mL?min^?1 and UV detection at 250?nm. The method was developed with a short run time of 1?min. Forced degradation studies revealed that the method was stability-indicating, suitable for both assay and in-vitro dissolution of a drug product. The method was found to be linear in the range of 28–84?µg?mL^?1, 2.8–22.7?µg?mL^?1 with a correlation coefficient of 0.9999 and 1.000 for assay and dissolution, respectively. The recovery values were found in the range of 100.1–101.7%. The method was validated according to ICH guidelines.     

Simultaneous Estimation of Atorvastatin Calcium, Ramipril and Aspirin in Capsule Dosage Form by RP-LC

A simple, sensitive, precise and accurate reversed phase liquid chromatographic method has been developed for the simultaneous estimation of atorvastatin (AT) calcium, ramipril (RA) and aspirin (AS) from capsule dosage form. The method was developed using a Phenomenex Luna C₁₈ (250 mm, 4.6 mm i.d., 5 µm) column with a mobile phase consisting of 0.1%, orthophosphoric acid buffer:acetonitrile:methanol (45:50:5 v/v/v), pH 3.3, at a flow rate of 1 mL min^?1. Detection was carried out with ultra-violet detection at 210 nm. The retention times were about 12.19, 2.35, and 3.95 min for AT calcium, RA and AS, respectively. The developed method was validated for linearity, accuracy, precision, limit of detection, limit of quantitation and robustness. The linearity ranges were 1–6 µg mL^?1 for AT calcium, 0.5–3 µg mL^?1 for RA and 7.5–45 µg mL^?1 for AS with mean recoveries of 100.59 ± 0.68, 100.62 ± 0.83 and 100.49 ± 0.73% for AT calcium, RA and AS, respectively. Limit of detection obtained were 29.85 ng mL^?1 for AT calcium, 4.71 ng mL^?1 for RA and 85.13 ng mL^?1 for AS. Impurity of salicylic acid was found in capsule dosage form at the retention time of about 4.84 min. The proposed method can be used for the estimation of these drugs in combined dosage forms.     

Simultaneous Determination of Cimetidine and Related Compounds in Pharmaceuticals by HPLC on a Porous Graphitic Carbon Column

A high-performance liquid chromatographic method has been developed for determination of cimetidine and its main related compounds, 4-hydroxymethyl-5-methylimidazol (MH), N-cyano-N',N''-dimethylguanidine (Carbonate), 1-methyl-3-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]sulfonyl]ethyl]guanidine (Guanidine), 2-cyano-1-methyl-3-[2-[[(5-methyl-1H-imidazol-4-yl)methyl]sulfonyl] (Sulfoxide), and 1-[(methylamino)[[2-[[(5-methyl-1H-imidazol-4-yl)methyl]sulfonyl]ethyl]amino]methylene]urea (Amide). Chromatographic separation was achieved on a porous graphitic carbon (PGC) column with a gradient 17:83 to 19:81 (v/v) acetonitrile-0.05 M potassium phosphate buffer containing 0.40% pentane sulfonic acid at pH 2.5. Analysis was performed at a flow-rate of 1 mL min^?1 and the detection wavelength was 228 nm. Calibration plots were linear in the concentration ranges 0.25 to 83 µg mL^?1 for cimetidine and Carbonate, 0.25 to 75 µg mL^?1 for Guanidine, Amide, and Sulfoxide, and 0.25 to 100 µg mL^?1 for MH, with correlation coefficients (R ²) between 0.9990 and 0.9998. The lowest detectable concentration of cimetidine and Amide was 0.07 µg mL^?1; for MH, Carbonate, Guanidine, and Sulfoxide it was 0.06 µg mL^?1. Method repeatability (intraday) and reproducibility (interday) was always less than 2% (n=5). The proposed liquid chromatographic method was successfully used for analysis of commercially available cimetidine dosage forms; recoveries were from 99.2 to 100.8%.     

Development and validation of a generic RP‐HPLC PDA method for the simultaneous separation and quantification of active ingredients in cold and cough medicines

A novel generic reverse phase high performance liquid chromatography (RP‐HPLC) method is developed and validated for simultaneous determination of seven pharmaceutically active ingredients, namely, acetaminophen, dextromethorphan, doxylamine, phenylephrine, guaifenesin, caffeine and aspirin. All seven ingredients were quantified in soft gel, syrup and tablet formulations of the over‐the‐counter US‐marketed products, as per the guidelines of the International Conference on Harmonization. The separation was achieved in a 16 min run time on an Agilent Zorbax Phenyl column using a gradient method with two mobile phases. Mobile phase A was 0.15% trifluoro acetic acid in purified water and while mobile phase B was a mixture of acetonitrile and methanol (750:250 v/v) with 0.02% trifluoro acetic acid. The flow rate was 1.0 mL min^?1 and injection volume was 10 μL. Detection was performed at 280 nm using a photodiode array detector. As part of the method validation, specificity, linearity, precision and recovery parameters were verified. The concentration and area relationships were linear (R² > 0.999), over the concentration ranges 20–120 μg mL^?1 for acetaminophen, 75–450 μg mL^?1 for dextromethorphan, 31.25–187.5 μg mL^?1 for doxylamine, 25–150 μg mL^?1 for phenylephrine, 25–150 μg mL^?1 for aspirin, 6.5–39 μg mL^?1 for caffeine and 12–72 μg mL^?1 for guaifenesin. The relative standard deviations for precision and intermediate precision were <1.5%. The proposed RP‐HPLC generic method is applicable for routine analysis of cold and cough over‐the‐counter products.     

Simple HPLC method for simultaneous determination of acetaminophen, caffeine and chlorpheniramine maleate in tablet formulations

Summary A simple, rapid and accurate, routine-HPLC method is described for simultaneous determination of acetaminophen, caffeine and chlorpheniramine maleate in a new tablet formulation Chromatographic separation of the three pharmaceuticals was achieved on a Hypersil CN column (150×5.0 mm, 5 μm) using a mobile phase comprising a mixture of acetonitrile, an ion-pair solution and tetrahydrofuran (13:14:87, v/v,pH4.5). The flow-rate was changed from 1.0 mL min⁻¹ (in 0≈7.5 min) to 1.8 mL min⁻¹ (after 3.5 min). was complete in <10 min. The method was validated for system suitability, linearity, accuracy, precision, limits of detection and quantitation, and robustness. Linearity, accuracy and precision were found to be acceptable over the ranges 31.6≈315.8 μg mL⁻¹ for acetaminophen, 9.5≈94.6 μg mL⁻¹ for caffeine and 1.4≈13.8 μg mL⁻¹ for chlorpheniramine maleate.     

A novel vortex-assisted liquid phase microextraction method for parabens in cosmetic oil products using deep eutectic solvent

ABSTRACT

The parabens, which are harmful to our bodies, are primarily utilized as preservatives in medicine, personal care products and cosmetics. A novel, more efficient, fast and cheap vortex-assisted liquid phase microextraction method based on deep eutectic solvents (DESs) was developed for the determination of parabens. The microextraction conditions were optimized using these solvents and the analytical parameters of the method were determined under optimal microextraction conditions. After extraction, the chromatographic separation of parabens was undertaken using high-performance liquid chromatography-UV detection. Experimental parameters, such as DES type, DES volume, dilution solvent volume and vortex extraction time were optimized. DES6 [ChCl-Ethylene glycol (1/2)] was the most suitable DES to work in this study. Detection limits for this method of 0.053 µg mL^?1 for methylparaben, 0.061 µg mL^?1 for ethylparaben, 0.049 µg mL^?1 for propylparaben and 0.052 µg mL^?1 for butylparaben were obtained. Correlation coefficients (R²) for a concentration range of 0.1–100 µg mL^?1 were higher than 0.9992 and relative standard deviation (RSD) values below 2.91% at parabens concentration of 2.5 µg mL^?1 were obtained. The results of spike/recovery values of real samples were greater than 84%. When compared with other methods, the main advantages include lower LOD, short extraction time, rapidity, repeatability and simplicity.     

A validated stability-indicating LC method for simultaneous determination of quinapril and hydrochlorothiazide in pharmaceutical samples

A stability-indicating liquid chromatographic method was developed and validated for simultaneous determination of quinapril and hydrochlorothiazide in drug substances and dosage forms. Chromatographic separation of quinapril, hydrochlorothiazide and its degradation products was achieved on a RP-18 column, using acetonitrile and phosphate buffer (pH 4.6) as mobile phase in a gradient mode and detection at 216 nm. Stress testing was performed under hydrolytic, oxidative, thermal and photolytic conditions. The degradation products were well resolved from main peaks, proving the stability-indicating power of the method. The assay was linear for quinapril and hydrochlorothiazide concentrations of 40–200 µg mL^?1 and 25–125 µg mL^?1, respectively. The developed method was selective, accurate and precise for quinapril and hydrochlorothiazide determination. This method was used to quantify both drugs in combined commercial tablets. The results showed that the proposed method was found to be suitable for quantitative determination and the stability study of quinapril and hydrochlorothiazide in pharmaceutical samples.      

RP-HPLC Method for Simultaneous Determination of Sofosbuvir and Ledipasvir in Tablet Dosage Form and Its Application to In Vitro Dissolution Studies

A reversed-phase high-performance liquid chromatographic method was developed for the simultaneous determination of sofosbuvir and ledipasvir in tablet dosage form. The analysis was performed on Luna analytical column 250 × 4.6 mm, 5 µm, octyl silica packing (Si–[CH₂]₇–CH₃) C8, using ammonium acetate buffer solution pH 7.0 and acetonitrile 35:65 % v/v as mobile phase at flow rate of 0.7 mL min⁻¹ for isocratic elution. Detection of sofosbuvir and ledipasvir was performed on a UV detector at 245 nm. The retention times of sofosbuvir and ledipasvir were 4.468 ± 0.013 min and 8.242 ± 0.012 min, respectively, and the total run time was 20 min. The method was validated according to the requirements of the United States Pharmacopeia (category I). The overall recovery of both analytes was 100 ± 1 %; the relative standard deviation for precision and intraday precision was less than 2.0 %. The method was linear with correlation coefficient (r) >0.9999, limits of detection 0.485 and 0.175 µg mL⁻¹, and limits of quantification was 1.619 and 0.586 µg mL⁻¹ for sofosbuvir and ledipasvir, respectively. The method was successfully applied to the assay and in vitro dissolution studies of sofosbuvir and ledipasvir in tablet dosage form.

     

Development of a green stability-indicating HPLC–DAD method for the determination of donepezil hydrochloride in the presence of its related substance and degradation products

A simple, eco-friendly, stability-indicating HPLC method was developed for the determination of donepezil hydrochloride (DH) in tablet dosage form in the presence of its pharmacopoeia-related compound (donepezil-related compound A) and its different degradation products. The chromatographic conditions were optimized to achieve the highest performance parameters using Zorbax Eclipse Plus C18 rapid resolution column (4.6?×?100?mm, 3.5?µm), with a mobile phase composed of 72.5% acetate buffer pH 5.5 and 27.5% ethanol, flowing at 1?mL?min^?1. The diode array detector (DAD) was set at 315?nm and the column oven was adjusted at 45°C. Linear response (r?=?0.9999) was observed over the range of 2–28?µg?mL^?1 of donepezil, with detection and quantitation limits of 0.031 and 0.103?µg?mL^?1, respectively. Forced degradation studies were performed on standard DH and test Demepezil® 5-mg tablets under various conditions and the method was found to be stability indicating. The purity of DH peak was confirmed using the DAD. In the developed method, two principles of green chromatography were adopted (reduce and replace) by reducing solvent consumption through the utilization of a short column (10?cm) with a smaller particle size (3.5?µm) instead of a normal 25?cm with a 5?µm particle size and by replacing hazardous solvents of the official United States Pharmacopoeia method as acetonitrile with ethanol. Furthermore, the greenness of the method was assessed using three assessment tools.     

Development and Validation of a High Performance Liquid Chromatographic Method for the Determination of Voriconazole Content in Tablets

This paper describes the validation of an isocratic HPLC method for the assay of voriconazole in tablets. The method employs a Merck LiChrospher^? 100 RP-8 (125 × 4.6 mm I.D., 5 μm particle size) column, with a mobile phase of methanol : triethylamine solutions 0.6 %, pH 6.0 (50:50, v/v) and UV detection at 255 nm. A linear response (r > 0.9999) was observed in the range of 20.0–100.0 μg mL⁻¹. The method showed good recoveries (average 100.4%) and the relative standard deviation intra and inter-day were ≤ 1.0 %. Validation parameters as specificity and robustness were also determined. The method can be used for both quality control assay of voriconazole in tablets and for stability studies as the method separates voriconazole from its degradation products and tablet excipients.     

Development and Validation of a Stability-Indicating HPLC Method for Determination of Ciprofloxacin Hydrochloride and its Related Compounds in Film-Coated Tablets

The objective of the current study was the development and subsequent validation of a simple, sensitive, precise and stability-indicating reversed-phase HPLC method for the determination of ciprofloxacin HCl in pharmaceutical dosage forms in the presence of its potential impurities. The chromatographic separation of ciprofloxacin HCl and its related compounds was achieved on an Inertsil ODS3 column using UV detection. The optimized mobile phase consisted of phosphoric acid solution: acetonitril. The proposed method provided linear responses within the concentration range 250–750 μg mL⁻¹ for ciprofloxacin HCl and 0.5–1.5 μg mL⁻¹ for its related compounds. LOD and LOQ values for the active substance were 5.159 and 15.632 μg mL⁻¹, respectively. Correlation coefficients (r) of the regression equations for the impurities were greater than 0.99 in all cases. The precision of the method was demonstrated using intra- and inter-day assay RSD% values which were less than 1% in all instances. No interference from any components of pharmaceutical dosage forms or degradation products was observed.

     

Simultaneous Determination of Dextromethorphan Hydrobromide, Pyrilamine Maleate and Sodium Benzoate in a Cough Cold Syrup by LC

A liquid chromatographic method for the simultaneous determination of dextromethorphan hydrobromide, pyrilamine maleate and sodium benzoate in cough cold syrup has been developed. The method was based on replacing heptane sulfonate by sodium chloride as ion pairing agent. The addition of sodium chloride to the mobile phase has changed the retention behaviour of the basic drugs. The separation of these compounds was achieved in less than 8 min with an isocratic mobile phase consisting of acetonitrile/0.1 M dihydrogenphosphate buffer containing 0.1 M sodium chloride (29:71 v/v) at pH 2.5 and using a Kromasil C18 column. The analysis was performed at a flow rate of 1 mL min^?1 and at a detection wavelength of 220 nm. The selectivity, linearity of calibration, accuracy, within and between days precision, limit of detection and quantification, recovery were examined as parts of the method validation. Calibration curves were linear in the range 1–140 μg mL^?1 with a regression coefficient (R ²) better than 0.999. The results of the method repeatability (intra-day) and reproducibility (inter-day) were all less than 2% (n = 6). The lowest detectable concentration of dextromethorphan hydrobromide and pyrilamine maleate varied between 0.10 and 0.12 μg mL^?1. The proposed liquid chromatographic method was satisfactorily applied for the routine quality control of dextromethorphan hydrobromide, pyrilamine maleate and sodium benzoate in cough cold syrup formulations.     

Determination of Ibandronate and its Degradation Products by Ion-Pair RP LC with Evaporative Light-Scattering Detection

A simple method has been developed for analysis of ibandronate and related substances by ion-pair reversed-phase high-performance liquid chromatography (RPIC) with evaporative light-scattering detection (ELSD). After optimization of the chromatographic conditions satisfactory separation of the compounds was achieved on an Intersil C₈ column with an isocratic mobile phase—8:4:88 (v/v) acetonitrile–methanol–12 mM ammonium acetate buffer containing 35 mM n-amylamine (pH 7.0). The mobile phase flow rate was 1.0 mL min^?1. The calibration plot was linear in the range 352 to 1760 µg mL^?1 for ibandronate. The precision and reproducibility were 0.3% and 0.5%, respectively. The average recovery of ibandronate was 100.4% and RSD was 0.6%. The method was validated and shown to be precise, accurate, and specific for assay of ibandronate in bulk material and dosage forms. The proposed liquid chromatographic method can be satisfactorily used for quality control of ibandronate.     

LC–MS–MS Simultaneous Determination of Paracetamol, Pseudoephedrine and Chlorpheniramine in Human Plasma: Application to a Pharmacokinetic Study

A liquid chromatography–tandem mass spectrometry (LC–MS–MS) method was developed for the simultaneous determination of paracetamol, pseudoephedrine and chlorpheniramine in human plasma. Diphenhydramine was used as the internal standard. Analytes were extracted from alkalized human plasma by liquid–liquid extraction (LLE) using ethyl acetate. After electrospray ionization positive ion fragments were detected in the selected reaction monitoring (SRM) mode with a triple quadrupole tandem mass spectrometer. The method was linear in the concentration range of 20.0–10000.0 ng mL^?1 for paracetamol, 1.0–500.0 ng mL^?1 for pseudoephedrine and 0.1–50.0 ng mL^?1 for chlorpheniramine. The intra- and inter-day precisions were below 14.5% and the bias was between ?7.3 and +2.8% for all analytes. The validated LC–MS–MS method was applied to a pharmacokinetic study in which each healthy Chinese volunteer received a tablet containing 300 mg benorylate, 30 mg pseudoephedrine hydrochloride and 2 mg chlorpheniramine maleate. This is the first assay method described for the simultaneous determination of paracetamol, pseudoephedrine and chlorpheniramine in human plasma samples.     

A Stability Indicating LC Method for Deferasirox in Bulk Drugs and Pharmaceutical Dosage Forms

A novel, sensitive, stability indicating RP-LC method has been developed for the quantitative determination of deferasirox, its related impurities in both bulk drugs and pharmaceutical dosage forms. Efficient chromatographic separation was achieved on a C18 stationary phase with simple mobile phase combination delivered in an isocratic mode and quantitation was by ultraviolet detection at 245 nm. The mobile phase consisted of buffer, acetonitrile and methanol (50:45:5, v/v) delivered at a flow rate of 1.0 mL min^?1. Buffer consisted of 10 mM potassium dihydrogen orthophosphate monohydrate, pH adjusted to 3.0 by using orthophosphoric acid. In the developed LC method the resolution (R _s ) between deferasirox and its four potential impurities was found to be greater than 2.0. Regression analysis showed an r value (correlation coefficient) greater than 0.999 for deferasirox and its four impurities. This method was capable to detect all four impurities of deferasirox at a level of 0.002% with respect to test concentration of 0.5 mg mL^?1 for a 10 μL injection volume. The inter- and intra-day precision values for all four impurities and for deferasirox was found to be within 2.0% RSD. The method showed good and consistent recoveries for deferasirox in bulk drugs (98.3–101.1%), pharmaceutical dosage forms (100.2–103.1%) and for its all the four impurities (99.7–102.1%). The test solution was found to be stable in methanol for 48 h. The drug was subjected to stress conditions of hydrolysis, oxidation, photolysis and thermal degradation. Considerable degradation was found to occur in acid stress hydrolysis. The stress samples were assayed against a qualified reference standard and the mass balance was found close to 99.95%. The developed RP-LC method was validated with respect to linearity, accuracy, precision and robustness.